# Marker Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2023

- Company: [Marker Therapeutics, Inc.](/companies/mrkr.md) (CIK 1094038)
- Form: 10-Q
- Filed: 2023-11-09
- Accepted by EDGAR: Nov 9, 2023, 21:31 ET
- Period: 2023-09-30
- Accession: 0001410578-23-002307
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1094038/000141057823002307/mrkr-20230930x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1094038/000141057823002307/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-07-01 to 2023-09-30 | $257.6k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months, 2023-01-01 to 2023-09-30 | $2.3m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Research and development | 3 months, 2023-07-01 to 2023-09-30 | $2.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2023-01-01 to 2023-09-30 | $7.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2023-07-01 to 2023-09-30 | −$3.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2023-01-01 to 2023-09-30 | −$11.6m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2023-07-01 to 2023-09-30 | −$3.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2023-01-01 to 2023-09-30 | −$5.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-07-01 to 2023-09-30 | −$0.34 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2023-01-01 to 2023-09-30 | −$0.62 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-07-01 to 2023-09-30 | −$0.34 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2023-01-01 to 2023-09-30 | −$0.62 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-07-01 to 2023-09-30 | 8,825,881 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2023-01-01 to 2023-09-30 | 8,834,512 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2023-01-01 to 2023-09-30 | −$14.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2023-09-30 | $17.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-09-30 | $19.5m | us-gaap:AssetsCurrent |
| Total assets | at 2023-09-30 | $19.5m | us-gaap:Assets |
| Current liabilities | at 2023-09-30 | $2.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-09-30 | $2.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2023-09-30 | $16.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 32,830 characters.

*This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, that involve risks and uncertainties. All statements other than statements relating to historical matters including statements to the effect that we “believe”, “expect”, “anticipate”, “plan”, “target”, “intend” and similar expressions should be considered forward-looking statements. Our actual results could differ materially from those discussed in the forward-looking statements as a result of a number of important factors, including factors discussed in this section and elsewhere in this Quarterly Report on Form 10-Q, and the risks discussed in our other filings with the SEC. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its potential impact on our business and the global economy. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis, judgment, belief, or expectation only as the date hereof. We assume no obligation to update these forward-looking statements to reflect events or circumstance that arise after the date hereof.*

*As used in this quarterly report: (i) the terms “we”, “us”, “our”, “Marker” and the “Company” mean Marker Therapeutics, Inc. and its wholly owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals Inc. which wholly owns GeneMax Pharmaceuticals Canada Inc., unless the context otherwise requires; (ii) “SEC” refers to the Securities and Exchange Commission; (iii) “Securities Act” refers to the Securities Act of 1933, as amended; (iv) “Exchange Act” refers to the Securities Exchange Act of 1934, as amended; and (v) all dollar amounts refer to United States dollars unless otherwise indicated.*

*The following should be read in conjunction with our unaudited condensed consolidated interim financial statements and related notes included in this Quarterly Report on Form 10-Q.*

### Company Overview

We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumor-associated antigens, or TAAs. multiTAA-specific T cells are able to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. When infused into a cancer patient, the multiTAA-specific T cells are designed to kill cancer cells expressing the TAA targets and potentially recruit the patient’s immune system to participate in the cancer killing process.

We licensed the underlying technology for multiTAA-specific T cell therapy from Baylor College of Medicine (“BCM”) in March 2018. BCM had utilized the therapy in seven exploratory clinical trials. In these studies, BCM treated over 200 patients suffering from a variety of cancers including lymphoma, multiple myeloma, acute myeloid leukemia, acute lymphoblastic leukemia and pancreatic cancer. In those studies, BCM saw evidence of clinical benefit, expansion of infused cells, epitope spreading, and decreased toxicity compared to other cellular therapies.

We are advancing three product candidates as part of our multiTAA-specific T cell program for:

1\. autologous treatment of lymphoma, and selected solid tumors,

2\. allogeneic T cells for the treatment of acute myeloid leukemia (“AML”), and

3\. off-the-shelf products in various indications

Our current clinical development programs are:

- MT-401 for the treatment of post-transplant AML,
- MT-401-OTS for the treatment of AML,
- MT-601 for the treatment of lymphoma, and
- MT-601 for the treatment of pancreatic cancer(1).

(1) Clinical advancement will be pending additional financial support from non-dilutive grant activities.

We are currently undertaking a strategic review of our clinical development programs, including with respect to clinical trial initiation and readout guidance.

We believe that the simplicity of our manufacturing process allows additional modifications to expand multiTAA-specific T cell recognition of cancer targets. In May 2023, we entered into a purchase agreement with Cell Ready, LLC with respect to our manufacturing facility and certain related assets. See “Recent Developments.”

### Pipeline

Our clinical-stage pipeline, including clinical trials being conducted by BCM and other partners, is set forth below:

### Recent Developments

On June 26, 2023, we completed the previously announced transaction with Cell Ready, LLC, or Cell Ready, pursuant to a Purchase Agreement, or the Cell Ready Purchase Agreement, dated May 1, 2023, by and between us and Cell Ready. Mr. John Wilson is a member of our board of directors and is serving as the CEO of Cell Ready, therefore Cell Ready is a related party. Pursuant to the Cell Ready Purchase Agreement, effective as of the Closing Date, we (i) assigned to Cell Ready the leases for our two manufacturing facilities in Houston, Texas, or the Manufacturing Facilities, (ii) sold to Cell Ready all of the equipment and leasehold improvements at the Manufacturing Facilities and (iii) assigned to Cell Ready our rights, title and interest in our Master Services Agreement for Product Supply, or the MSA, dated April 7, 2023, by and between us, Cell Ready and Indapta Therapeutics, Inc. (“Indapta”) as well as our rights, title and interest in any contracts related to the equipment and Manufacturing Facilities (collectively referred to as the “Purchased Assets”). Following the Closing Date, we and Cell Ready have agreed to enter a long-term contract pursuant to which Cell Ready will perform a wide variety of services for us, including research and development, manufacturing, and regulatory activity in support of our clinical trials; however, the parties have not yet executed such agreement. Cell Ready acquired the Purchased Assets for total consideration of $19.0 million. In connection with the purchase of the Manufacturing Facilities, Cell Ready also extended offers of employment to approximately 50 of our former employees in our manufacturing, development, quality and regulatory affairs functions.

In May 2023, we announced that we had received a $2.0 million grant from the National Institutes of Health Small Business Innovation Research program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents. The Company has not received any funds associated with this grant.

In August 2023, we announced non-clinical data of its lead multiTAA-specific T cell product candidate, MT-401, in an Off-the-Shelf (OTS) setting and provided an update on clinical readiness for the OTS program. We anticipats that the first patient will be treated with MT-401 OTS in 2024.

In September 2023, we announced preliminary results of the first participant treated with MT-601 in our Phase 1 multicenter APOLLO clinical trial. After relapse following anti-CD19 CAR T cell therapy, the participant was treated with two doses of MT-601 at the 200 million cell dose level without prior lymphodepletion. MT-601 treatment was well tolerated with no reports of higher than Grade 1 treatment-related adverse events. The tolerability at this initial dose level is consistent with the favorable clinical safety profile and tolerability previously reported for other multiTAA-specific T cell products. Eight weeks after the 2nd infusion of MT-601, the participant demonstrated complete metabolic response based on PET-CT scans. We are treating and evaluating additional patients in the Phase 1 APOLLO trial and anticipate reporting additional data in the first quarter of 2024.

### Organizational Changes

In May and June 2023, we implemented changes to our organizational structure as part of an operational cost reduction plan and reorganization plan due to the transaction with Cell Ready. In connection with these changes, we reduced headcount, including the separation of our former Chief Executive Officer, Peter Hoang, and our former Chief Accounting Officer, Michael Loiacono. During the second quarter of 2023, we recorded $0.9 million of severance and termination-related costs. The payment of these costs were completed in July of 2023.

Effective May 1, 2023, our board of directors appointed Dr. Vera as our Chief Executive Officer. Effective June 30, 2023, our board of directors appointed Eliot M. Lurier as our Interim Chief Financial Officer. Mr. Lurier provides consulting services to us pursuant to a consulting agreement between us and Danforth Advisors, LLC and receives no compensation directly from us.

### Reverse Stock Split

On January 26, 2023, we effected the Reverse Stock Split and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All historical share and per share amounts reflected in this report have been adjusted to reflect the Reverse Stock Split.

### Results of Operations

In this discussion of our results of operations and financial condition, amounts in financial tables, other than per-share amounts, have been rounded to the nearest thousand.

### Comparison of the Three months Ended September 30, 2023 and 2022

The following table summarizes the results of our continuing operations for the three months ended September 30, 2023 and 2022:

| ​ ​ ​ ​ Revenues: | ​ ​ ​ | ​ ​ For the Three Months Ended September 30, 2023 ​ | ​ | ​ ​ 2022 ​ | ​ ​ ​ | ​ ​ ​ ​ ​ ​ Change ​ | ​ ​ ​ | ​ ​ ​ ​ ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Grant income | ​ | $258,000 | ​ | $1,000,000 | ​ | $(742,000) |  | (74)% |
| Total revenues | ​ | 258,000 | ​ | 1,000,000 | ​ | (742,000) |  | (74)% |
| **Operating expenses:** | ​ | ​ | ​ | ​ | ​ |  |  | ​ |
| Research and development | ​ | 2,045,000 | ​ | 3,592,000 | ​ | (1,547,000) |  | (43)% |
| General and administrative | ​ | 1,413,000 | ​ | 3,234,000 | ​ | (1,821,000) |  | (56)% |
| Total operating expenses | ​ | 3,458,000 | ​ | 6,826,000 | ​ | (3,368,000) |  | (49)% |
| Loss from operations | ​ | (3,200,000) | ​ | (5,826,000) | ​ | 2,626,000 |  | (45)% |
| **Other income (expenses):** | ​ | ​ | ​ | ​ | ​ | ​ |  | ​ ​ |
| Arbitration settlement | ​ | ​ — | ​ | ​ — | ​ | ​ — | ​ | 0% |
| Interest income | ​ | 218,000 | ​ | 100,000 | ​ | 118,000 |  | 118% |
| Loss from continuing operations before income taxes | ​ | ​ (2,982,000) | ​ | ​ (5,726,000) | ​ | ​ 2,744,000 | ​ | (48)% |
| Loss from continuing operations | **​** | **$(2,982,000)** | **​** | **$(5,726,000)** | **​** | **$2,744,000** |  | **(48)%** |

### Revenue

We did not generate any revenue during the three months ended September 30, 2023 and 2022, respectively, from the sales or licensing of our product candidates.

In August 2021, we received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (“CPRIT”) to support our Phase 2 clinical trial of MT-401. During the three months ended September 30, 2023, we recognized $0.2 million of revenue associated with the CPRIT grant.

In September 2022, we received notice from the FDA that it had awarded us a $2.0 million grant from the FDA’s Orphan Products Grant program to support our Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. During the three months ended September 30, 2023, we recognized $16,000 of revenue associated with the FDA grant and $0 in the same period ended 2022.

### Operating Expenses

Operating expenses incurred during the three months ended September 30, 2023 were $3.5 million compared to $6.8 million during the same period ended September 30, 2022.

Significant changes and expenditures in operating expenses are outlined as follows:

#### Research and Development Expenses

Research and development expenses decreased by 43% to $2.0 million for the three months ended September 30, 2023, compared to $3.6 million for the three months ended September 30, 2022.

The decrease of $1.6 million in 2023 was primarily attributable to the following:

- decrease of $1.0 million in process development expenses,
- decrease of $0.5 million in clinical trial expenses,
- decrease of $0.4 million in headcount-related expenses,
- decrease of $0.1 million in other expenses, offset by
- increase of $0.4 million in Cell Ready production costs.

#### General and Administrative Expenses

General and administrative expenses decreased by 56% to $1.4 million for the three months ended September 30, 2023, compared to $3.2 million during the same period ended September 30, 2022.

The decrease of $1.8 million in 2023 was primarily attributable to the following:

- decrease of $0.7 million in stock-based compensation expenses,
- decrease of $1.0 million in headcount-related expenses, and
- decrease of $0.1 million in professional services expenses.

### Other Income (Expense)

#### Interest Income

Interest income was $0.2 million and $0.1 million for the three months ended September 30, 2023 and 2022, respectively, and was attributable to interest income relating to funds that are held in U.S. Treasury notes and U.S. government agency-backed securities.

### Comparison of the Nine months Ended September 30, 2023 and 2022

The following table summarizes the results of our continuing operations for the nine months ended September 30, 2023 and 2022:

| ​ ​ ​ ​ Revenues: | ​ ​ ​ | ​ ​ For the Nine Months Ended September 30, 2023 ​ ​ | ​ ​ | ​ ​ 2022 ​ ​ | ​ ​ ​ | ​ ​ ​ ​ ​ Change ​ ​ | ​ ​ | ​ ​ ​ ​ ​ |
| --- | --- | --- | --- | --- | --- | --- | --- | ---: |
| Grant income | **​** | $2,255,000 | ​ | $2,754,000 | **​** | $(499,000) | **​** | (18)% |
| Total revenues |  | ​ 2,255,000 |  | ​ 2,754,000 |  | ​ (499,000) |  | (18)% |
| **Operating expenses:** |  | ​ ​ |  | ​ ​ |  | ​ ​ |  | ​ |
| Research and development |  | ​ 7,799,000 |  | ​ 9,786,000 |  | ​ (1,987,000) |  | (20)% |
| General and administrative |  | ​ 6,099,000 |  | ​ 9,721,000 |  | ​ (3,622,000) |  | (37)% |
| Total operating expenses |  | ​ 13,898,000 |  | ​ 19,507,000 |  | ​ (5,609,000) |  | (29)% |
| Loss from operations |  | ​ (11,643,000) |  | ​ (16,753,000) |  | ​ 5,110,000 |  | (31)% |
| **Other income (expenses):** |  | ​ ​ |  | ​ ​ |  | ​ ​ |  | ​ ​ |
| Arbitration settlement | ​ | ​ — | ​ | ​ (119,000) | ​ | ​ 119,000 | ​ | (100)% |
| Interest income |  | ​ 338,000 |  | ​ 139,000 |  | ​ 199,000 |  | 143% |
| Loss from continuing operations before income taxes | ​ | ​ (11,305,000) | ​ | ​ (16,733,000) | ​ | ​ 5,428,000 | ​ | (32)% |
| Loss from continuing operations | **​** | **$(11,305,000)** | **​** | **$(16,734,000)** | **​** | **$5,429,000** |  | **(32)%** |

### Revenue

We did not generate any revenue during the nine months ended September 30, 2023 and 2022, respectively, from the sales or licensing of our product candidates.

In August 2021, we received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas to support our Phase 2 clinical trial of MT-401. During the nine months ended September 30, 2023, we recognized $2.1 million of revenue associated with the CPRIT grant.

In September 2022, we received notice from the FDA that it had awarded us a $2.0 million grant from the FDA’s Orphan Products Grant program to support our Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. During the nine months ended September 30, 2023, we recognized $0.2 million of revenue associated with the FDA grant and $0 in the same period ended 2022.

### Operating Expenses

Operating expenses incurred during the nine months ended September 30, 2023 were $13.9 million compared to $19.5 million during the same period ended September 30, 2022.

Significant changes and expenditures in operating expenses are outlined as follows:

#### Research and Development Expenses

Research and development expenses decreased by 20% to $7.8 million for the nine months ended September 30, 2023, compared to $9.8 million for the same period ended September 30, 2022.

The decrease of $2.0 million in 2023 was primarily attributable to the following:

- decrease of $1.4 million in process development expenses,
- decrease of $0.3 million in stock-based compensation expenses,
- decrease of $0.6 million in headcount-related expenses
- decrease of $0.5 million in sponsored research expenses from BCM agreements,
- decrease of $0.3 million in clinical trial expenses, offset by
- increase of $0.5 million in professional services expenses.
- increase of $0.4 million in Cell Ready production costs, and
- increase of $0.2 million in other expenses.

#### General and Administrative Expenses

General and administrative expenses decreased by 37% to $6.1 million for the nine months ended September 30, 2023, compared to $9.7 million for the same period ended September 30, 2022.

The decrease of $3.6 million in 2023 was primarily attributable to the following:

- decrease of $1.9 million in stock-based compensation expenses,
- decrease of $1.1 million in headcount-related expenses,
- decrease of $0.5 million in rent expenses, and
- decrease of $0.1 million in other expenses.

### Other Income (Expense)

#### Interest Income

Interest income was $0.3 million and $0.1 million for the nine months ended September 30, 2023 and 2022, respectively, and was attributable to interest income relating to funds that are held in U.S. Treasury notes and U.S. government agency-backed securities.

#### Arbitration Settlement

An arbitration proceeding was brought against us before the FINRA by a broker seeking to be paid compensation for two financing transactions that occurred in 2018, a warrant conversion and a private placement brokered by another broker. The FINRA panel found in favor of the broker and awarded the broker $2.4 million for compensation, interest, and attorney fees, which we recorded in the year ended December 31, 2021. During the nine months ended September 30, 2022, we recorded an additional $0.1 million of expense related to this matter.

### Liquidity and Capital Resources

We have not generated any revenue from product sales since inception. We have financed our operations primarily through public and private offerings of our debt and equity securities.

### Cash and Working Capital

The following table sets forth our cash and cash equivalents and working capital as of September 30, 2023 and December 31, 2022:

| ​ ​ ​ | ​ ​ | ​ ​ September 30, 2023 | ​ ​ | ​ ​ December 31, 2022 |
| --- | --- | ---: | --- | ---: |
| Cash and cash equivalents | ​ | $17,474,000 | ​ | $11,782,000 |
| Working capital | ​ | $16,707,000 | ​ | $8,837,000 |

### Cash Flows

The following table summarizes our cash flows for the three months ended September 30, 2023 and 2022:

| ​ ​ ​ ​ Net cash provided by (used in): | ​ ​ ​ | ​ ​ For the Nine Months Ended September 30, 2023 ​ | ​ | ​ ​ 2022 ​ |
| --- | --- | ---: | --- | ---: |
| Operating activities | ​ | $(14,072,000) | ​ | $(20,667,000) |
| Investing activities | ​ | 18,664,000 | ​ | (4,819,000) |
| Financing activities | ​ | 1,100,000 | ​ | 64,000 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | ​ | $5,692,000 | ​ | $(25,422,000) |

As of September 30, 2023 and December 31, 2021, the Company had $107,530 and $1,146,186 of restricted cash, respectively.

#### Operating Activities

Net cash used in operating activities during the nine months ended September 30, 2023 was ($14.1) million compared to ($20.7) million for the same period last year.

Net cash used in operating activities during the nine months ended September 30, 2023 was due to ($11.3) million of net losses from continuing operations partially offset by $0.7 million of stock-based compensation, and changes in operating assets and liabilities of $2.5 million, plus ($6.0) million of cash used in discontinued operations.

Net cash used in operating activities during the nine months ended September 30, 2022 was due to ($16.7) million of net losses from continuing operations combined with changes in operating assets and liabilities of ($3.3) million and gain on the termination of leases of ($0.3) million, partially offset by stock-based compensation of $2.9 million, plus ($3.3) million of cash used in discontinued operations.

#### Investing Activities

Net cash provided by investing activities was $18.7 million primarily from the sale of assets of discounted operations during the nine months ended September 30, 2023.

Net cash used in investing activities was ($4.8) million for the purchase of property and equipment and construction in progress related to our manufacturing facility during the nine months ended September 30, 2022.

#### Financing Activities

Net cash provided by financing activities was $1.1 million during the nine months ended September 30, 2023, due to sales of common stock under the ATM Agreement and the Lincoln Park Purchase Agreement (as defined below).

Net cash provided by financing activities was $0.1 million during the nine months ended September 30, 2022, due to sales of common stock.

### Future Capital Requirements

To date, we have not generated any revenues from the commercial sale of approved drug products, and we do not expect to generate substantial revenue for at least the next several years. If we fail to complete the development of our product candidates in a timely manner or fail to obtain their regulatory approval, our ability to generate future revenue will be compromised. We do not know when, or if, we will generate any revenue from our product candidates, and we do not expect to generate significant revenue unless and until we obtain regulatory approval of, and commercialize, our product candidates. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or initiate clinical trials of and seek marketing approval for our product candidates. In addition, if we obtain approval for any of our product candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing, and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.

In August 2021, we received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support our Phase 2 clinical trial of MT-401. The CPRIT award is intended to support the adjuvant arm of the Company’s Phase 2 clinical trial evaluating MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia following a hematopoietic stem cell transplant. The primary objectives of the adjuvant arm of the trial are to evaluate relapse-free survival after MT-401 treatment when compared with a randomized control group. To date, we have received $6.9 million of funds from the CPRIT grant.

In September 2022, we received notice from the U.S. Food and Drug Administration that it had awarded us a $2.0 million grant from the FDA’s Orphan Products Grant program to support our Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. To date, we have received $0.2 million of funds from the FDA grant.

On June 26, 2023, we completed the previously announced transaction with Cell Ready. Pursuant to the Cell Ready Purchase Agreement, effective as of the Closing Date, we assigned and sold, as applicable, the Purchased Assets to Cell Ready. Following the Closing Date, we and Cell Ready have agreed to enter a long-term contract pursuant to which Cell Ready will perform a wide variety of services for us, including research and development, manufacturing, and regulatory activity in support of our clinical trials; however, the parties have not yet executed such agreement. Cell Ready acquired the Purchased Assets for total consideration of $19.0 million. In connection with the purchase of the Manufacturing Facilities, Cell Ready also extended offers of employment to approximately 50 of our former employees in our manufacturing, development, quality, and regulatory affairs functions.

As of September 30, 2023, we had working capital of $16.7 million, compared to working capital of $8.8 million as of December 31, 2022. Based on our clinical development plans and the disposition of the Purchased Assets pursuant to the Cell Ready Purchase Agreement and related organizational restructuring, we expect that our cash and cash equivalents as of September 30, 2023 will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Furthermore, our operating plans may change, and we may need additional funds sooner than planned to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates and the extent to which we may enter additional collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials.

Our future funding requirements will depend on many factors, as we:

- initiate or continue clinical trials of our product candidates;
- continue the research and development of our product candidates and seek to discover additional product candidates;seek regulatory approvals for our product candidates if they successfully complete clinical trials;
- enter into contract manufacturing arrangements with Cell Ready or other contract manufacturing organizations for clinical manufacturing supply;
- establish sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;
- evaluate strategic transactions we may undertake; and
- enhance operational, financial and information management systems and hire additional personnel, including personnel to support development of our product candidates and, if a product candidate is approved, our commercialization efforts.

Because all our product candidates are in the early stages of clinical and preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of product candidates or whether, or when, we may achieve profitability. Until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements.

We plan to continue to fund our operations and capital funding needs through existing cash and future equity and/or debt financing. We may also consider new collaborations or selectively partner our technology. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our existing stockholders’ common stock. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms unfavorable to us. We may also be required to pay damages or have liabilities associated with litigation or other legal proceedings involving our company.

The COVID-19 pandemic, decades-high inflation, and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company’s business and the value of its common stock.

### ATM Agreement

In August 2021, we entered a Controlled Equity OfferingSM Sales Agreement (the “ATM Agreement”) with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC (the “Sales Agents”), pursuant to which we can offer and sell, from time to time at our sole discretion through the Sales Agents, shares of our common stock having an aggregate offering price of up to $75.0 million. Any shares of our common stock sold will be issued pursuant to our shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021. The shelf registration statement on Form S-3 includes a prospectus supplement covering the offering up to a value of $9.87 million of shares of common stock over the 12 months ending March 22, 2024 pursuant to General Instruction I.B.6 of Form S-3, which limits the amounts that the Company may sell under the registration statement, and in accordance with the ATM agreement. The Sales Agents will be entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and we have provided each of the Sales Agents with indemnification and contribution rights. During the nine months ended September 30, 2023, the Company sold 265,334 shares of its common stock under the ATM Agreement for proceeds of $1.0 million.

### Stock Purchase Agreement

In December 2022, we entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”) which provides that, upon the terms and subject to the conditions of the Purchase Agreement, we have the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of our common stock (the “Purchase Shares”) from time to time over a 24-month term, at a variable price with certain market-based terms as defined in the Purchase Agreement. The Purchase Agreement does not exhibit any of the characteristics for liability classification under ASC Topic 480, Distinguishing Liabilities from Equity. Instead, the purchase agreement is indexed to the Company’s own stock under ASC Subtopic 815-40, Contracts in Entity’s Own Equity, and classified as equity. In January 2023, Lincoln Park was issued 180,410 shares of stock as a commitment fee at a value of $0.5 million. During the nine months ended September 30, 2023, we sold 12,500 shares of our common stock under the Purchase Agreement for proceeds of approximately $33,000.

### Critical Accounting Policies

The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the condensed consolidated financial statements and the judgments and assumptions used are consistent with those described under Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2022.

## Market risk

As filed, 153 characters.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

## Controls and procedures

As filed, 2,531 characters.

### (a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and our principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on such evaluation, our Chief Executive Officer and our Interim Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in recording, processing, summarizing, and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act.

It should be noted that any system of controls is based in part upon certain assumptions designed to obtain reasonable (and not absolute) assurance as to its effectiveness, and there can be no assurance that any design will succeed in achieving its stated goals.

Management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected.

### (b) Changes in Internal Control Over Financial Reporting

There have been no changes in our internal controls over financial reporting during the three and nine months ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 7,780 characters.

Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. In addition to the other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors described in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on March 12, 2023. There have been no material changes to the risk factors described in that report, other than as described below.

### We may not realize the expected benefits from the transaction with Cell Ready.

We may not be able to achieve the full strategic and financial benefits expected to result from the closing of the transaction with Cell Ready, or such benefits may be delayed or not occur at all. In particular, we have made the strategic decision to dispose of our manufacturing facilities and related assets in order to focus on clinical development of the multiTAA-specific T cell therapy-based product candidates in our pipeline. Following the closing of the transaction, we no longer operate our own cGMP manufacturing facility and must rely on third parties for the clinical and, if approved, commercial manufacture of our product candidates. Although we intend to enter into a long-term agreement with Cell Ready for manufacturing, among other services, we have not yet executed such agreement and may not realize the anticipated cost savings associated with contracting out our manufacturing, research and development and regulatory requirements. The assumptions we made related to the Cell Ready transaction may prove to be inaccurate, including as to the expected benefits of the transaction and anticipated cost savings. Further, the transition activities following closing may disrupt our operations and divert management’s attention to our business, particularly because our Chief Executive Officer, Dr. Juan Vera, expects to perform consulting work for Cell Ready in addition to his duties for our company. An inability to realize the anticipated benefits of the Cell Ready transaction could have an adverse impact on our business, financial condition and results of operations.

***Following the closing of the transaction with Cell Ready, we no longer operate our own cGMP manufacturing facility and instead will rely on third parties, including Cell Ready, for the clinical and, if approved, commercial manufacture of our product candidates. The third-party manufacturing facilities on which we rely may have limited capacity or fail to meet the applicable stringent regulatory requirements.***

We do not have any cGMP manufacturing facilities. We currently rely, and expect to continue to rely, on third parties for the cGMP manufacture of our product candidates for clinical development and, if approved, commercial supply. We intend to enter into a long-term agreement with Cell Ready, pursuant to which Cell Ready will perform a wide variety of services for us, including research and development, manufacturing and regulatory activity in support of our clinical trials; however, we have not yet executed such agreement. There is no guarantee that we will or have properly estimated our required manufacturing capacities or that the third parties we rely on to provide required machinery and materials for the manufacturing process will be able to perform on our proposed timelines or meet our manufacturing demands, if at all. Also, if we must increase production capacity for any reason, we may need to make considerable investments that could lead to significant financing needs or require us to enter into subcontracting agreements in order to outsource part of the production.

If Cell Ready or any other third-party contract manufacturing organization on which we rely experiences capacity constraints, other disruptions, or delays in manufacturing our multiTAA-specific T cell therapy-based product candidates, our planned clinical trials and necessary manufacturing capabilities will be disrupted or delayed. Third-party manufacturers may not be able to meet our needs concerning timing, quantity, or quality. If we are unable to contract for a sufficient supply of needed materials on acceptable terms, or if we should encounter delays or difficulties in our relationships with manufacturers, our clinical trials may be delayed, thereby delaying the submission of product candidates for regulatory approval or the market introduction and subsequent sales of any approved products. Any such delay may lower our revenues and potential profitability. If any third party breaches or terminates its agreement with us or fails to conduct its activities in a timely manner, the commercialization of our product candidates could be slowed down or blocked completely. It is possible that third parties relied upon by us will change their strategic focus, pursue alternative technologies, or develop alternative product candidates, either on their own or in collaboration with others, as a means for developing treatments for the diseases targeted by our collaborative programs, or for other reasons. The effectiveness of these third parties in marketing their own products may also affect our revenues and earnings. We intend to continue to enter into additional third-party agreements in the future. However, we may not be able to negotiate any additional agreements successfully. Even if established, these relationships may not be scientifically or commercially successful.

The facilities used by our contract manufacturers to manufacture our product candidates must be inspected by the FDA. We do not have control over a supplier’s or manufacturer’s compliance with laws, regulations and applicable cGMP standards or similar regulatory requirements and other laws and regulations, such as those related to environmental health and safety matters. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, we may be unable to obtain regulatory approval of our marketing applications. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.

Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supply of our products.

These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully, if approved. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue.

Filed Nov 9, 2023.
Source: SEC EDGAR, the filing index for accession 0001410578-23-002307. Last ingested by Listed: Oct 24, 2026, 15:02 ET. No prices; not investment advice.
